Liver metastases in patients with sarcoma are rare and associated with a poor prognosis. The experience with liver-directed therapies, eg hepatic arterial infusion, in these patients is limited.
Methods
Six patients with sarcoma metastatic to the liver (4 patients with gastrointestinal stromal tumors and 2 patients with leiomyosarcoma) were treated by hepatic arterial infusion in our center over a 12-year period. Since the experience was limited, a pooled analysis of reports with data on survival of 22 individual patients was performed.
Results
None of the 5 assessable patients responded to the therapy, and liver metastases progressed in all patients. The median survival was 20 months. In the pooled analysis, partial response was observed in 10 of 21 assessable patients (48%) and median survival was 20 months. The survival was significantly longer in responding patients compared to nonresponders (35 vs 14 months; logrank test, P= 0.009).
Conclusions
Hepatic arterial infusion has little efficacy in the treatment of sarcoma metastatic to the liver. More promising results have been reported for chemoembolization. The survival of responding patients seems to be better compared to non-responders.
Meta-Analysis Group in Cancer:Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.J Natl Cancer Inst,88: 252–258, 1996.
2.
EarlamS., GloverC., DaviesM., FordyC., Allen-MershT.G.: Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients.J Clin Oncol,15: 2022–2029, 1997.
StehlinJ.S., de IpolyiP.D., GreeffP.J., McGaffC.J., DavisB.R., McNaryL.: Treatment of cancer of the liver. Twenty years’ experience with infusion and resection in 414 patients.Ann Surg,208: 23–35, 1988.
5.
MiettinenM., LasotaJ.: Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.Virchows Arch,438: 1–12, 2001.
6.
DemetriG.D., von MehrenM., BlankeC.D., van den AbbeeleA.D., EisenbergB., RobertsP.J., HeinrichM.C., TuvesonD.A., SingerS., JanicekM., FletcherJ.A., SilvermanS.G., SilbermanS.L., CapdevilleR., KieseB., PengB., DimitrijevicS., DrukerB.J., CorlessC., FletcherC.D.M., JoensuuH.: Efficacy and safety of imabinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med,347: 472–480, 2002.
7.
BengtssonG., CarlssonG., HafstromL., JonssonP.E.: Natural history of patients with untreated liver metastases from colorectal cancer.Am J Surg,141: 586–589, 1981.
8.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment.Cancer,47: 207–214, 1981.
9.
FiorentiniG., BernardesciP., De SimoneM., RossiS., DenticoP., BiancalaniM., ScuderiS., VairaM., PalombaA.: Efficacy of imatinib mesylate in patients with liver metastases from gastrointestinal stromal tumor failing intra-arterial hepatic chemotherapy with epirubicin.J Exp Clin Cancer Res,22(Suppl): 13–16, 2003.
10.
MavligitG.M., ZukwiskiA.A., EllisL.M., ChuangV.P., WallaceS.: Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine.Cancer,75: 2083–2088, 1995.
11.
NgE.H., PollockR.E., RomsdahlM.M.: Prognostic implications of patterns of failure for gastrointestinal leiomyosarcoma.Cancer,69: 1334–1341, 1992.
12.
DeMatteoR.P., LewisJ.J., LeungD., MudanS.S., WoodruffJ.M., BrennanM.F.: Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival.Ann Surg,231: 51–58, 2000.
13.
BedikianA.Y., KhankhanianN., ValdiviesoM., HeilbrunL.K., BenjaminR.S., YapB.S., NelsonR.S., BodeyG.P.: Sarcoma of the stomach: clinicopathologic study of 43 cases.J Surg Oncol,13: 121–127, 1980.
14.
DeMatteoR.P., ShahA., FongY., JarnaginW.R., BlumgartL.H., BrennanM.F.: Results of hepatic resection for sarcoma metastatic to liver.Ann Surg,234: 540–548, 2001.
15.
CrosbyJ.A., CattonC.N., DavisA., CoutureJ., O'SullivanB., KandelR., SwallowC.J.: Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database.Ann Surg Oncol,8: 50–59, 2001.
16.
Van GlabbekeM., van OosteromA.T., OosterhuisJ.W., MouridsenH., CrowtherD., SomersR., VerweijJ., SantoroA., BuesaJ., TurszT.: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2185 patients treated with anthracycline-containing first-line regimens: a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.J Clin Oncol,17: 150–157, 1999.
17.
DeMatteoR.P., HeinrichM.C., El-RifaiW.M., DemetriG.: Clinical management of gastrointestinal stromal tumors: before and after STI-571.Human Pathol,33: 466–477, 2002.
18.
EdmonsonJ.H., MarksR.S., BucknerJ.C., MahoneyM.R.: Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.Cancer Invest,20: 605–612, 2002.
19.
PlaatB.E.C., HollemaH., MolenaarW.M., BroersG.H.T., PijpeJ., MastikM.F., HoekstraH.J., van den BergE., ScheperR.J., van der GraafW.T.A.: Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.J Clin Oncol,18: 3211–3220, 2000.
20.
RajanD.J., SoulenM.C., ClarkT.W.I., BaumR.A., HaskalZ.J., Shlansky-GoldbergR.D., FreimanD.B.: Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol chemoembolization.J Vasc Interv Radiol,12: 187–193, 2001.
21.
CarsonW., KarakousisC., DouglassH., RaoU., PalmerM.L.: Results of aggressive treatment of gastric sarcoma.Ann Surg Oncol,1: 244–251, 1994.
22.
LangH., NussbaumK.T., KaudelP., FruhaufN., FlemmingP., RaabR.: Hepatic metastases from leiomyosarcoma. A single-center experience with 34 resections during a 15-year period.Ann Surg,231: 500–505, 2000.
23.
EliasD., Cavalcanti de AlbuquerqueA., EggenspielerP., PlaudB., DucreuxM., SpielmannM., TheodoreC., BonvalotS., LasserP.: Resection of liver metastases from a noncolorectal primary: Indications and results based on 147 monocentric patients.J Am Coll Surg,187: 487–493, 1998.
24.
ChenH., PruittA., NicolT.L., GorguluS., ChotiM.A.: Complete hepatic resection of metastases from leiomyosarcoma prolongs survival.J Gastrointest Surg,2: 151–155, 1998.
